tetano
Editor, Senior Moderator
Cell Rep
. 2021 Apr 3;109017.
doi: 10.1016/j.celrep.2021.109017. Online ahead of print.
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
Markus Hoffmann[SUP] 1 [/SUP], Lu Zhang[SUP] 2 [/SUP], Nadine Kr?ger[SUP] 3 [/SUP], Luise Graichen[SUP] 3 [/SUP], Hannah Kleine-Weber[SUP] 2 [/SUP], Heike Hofmann-Winkler[SUP] 3 [/SUP], Amy Kempf[SUP] 2 [/SUP], Stefan Nessler[SUP] 4 [/SUP], Joachim Riggert[SUP] 5 [/SUP], Martin Sebastian Winkler[SUP] 6 [/SUP], Sebastian Schulz[SUP] 7 [/SUP], Hans-Martin J?ck[SUP] 7 [/SUP], Stefan P?hlmann[SUP] 8 [/SUP]
Affiliations
Abstract
Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from humans to farmed mink has been observed in Europe and the US. In the infected animals, viral variants arose that harbored mutations in the spike (S) protein, the target of neutralizing antibodies, and these variants were transmitted back to humans. This raised concerns that mink might become a constant source of human infection with SARS-CoV-2 variants associated with an increased threat to human health and resulted in mass culling of mink. Here, we report that mutations frequently found in the S proteins of SARS-CoV-2 from mink are mostly compatible with efficient entry into human cells and its inhibition by soluble angiotensin-converting enzyme 2 (ACE2). In contrast, mutation Y453F reduces neutralization by an antibody with emergency use authorization for coronavirus disease 2019 (COVID-19) therapy and sera/plasma from COVID-19 patients. These results suggest that antibody responses induced upon infection or certain antibodies used for treatment might offer insufficient protection against SARS-CoV-2 variants from mink.
Keywords: SARS-CoV-2; Y453F; antibodies; evasion; mink; mutation; neutralization; spike protein; variant.
. 2021 Apr 3;109017.
doi: 10.1016/j.celrep.2021.109017. Online ahead of print.
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
Markus Hoffmann[SUP] 1 [/SUP], Lu Zhang[SUP] 2 [/SUP], Nadine Kr?ger[SUP] 3 [/SUP], Luise Graichen[SUP] 3 [/SUP], Hannah Kleine-Weber[SUP] 2 [/SUP], Heike Hofmann-Winkler[SUP] 3 [/SUP], Amy Kempf[SUP] 2 [/SUP], Stefan Nessler[SUP] 4 [/SUP], Joachim Riggert[SUP] 5 [/SUP], Martin Sebastian Winkler[SUP] 6 [/SUP], Sebastian Schulz[SUP] 7 [/SUP], Hans-Martin J?ck[SUP] 7 [/SUP], Stefan P?hlmann[SUP] 8 [/SUP]
Affiliations
- PMID: 33857422
- DOI: 10.1016/j.celrep.2021.109017
Abstract
Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from humans to farmed mink has been observed in Europe and the US. In the infected animals, viral variants arose that harbored mutations in the spike (S) protein, the target of neutralizing antibodies, and these variants were transmitted back to humans. This raised concerns that mink might become a constant source of human infection with SARS-CoV-2 variants associated with an increased threat to human health and resulted in mass culling of mink. Here, we report that mutations frequently found in the S proteins of SARS-CoV-2 from mink are mostly compatible with efficient entry into human cells and its inhibition by soluble angiotensin-converting enzyme 2 (ACE2). In contrast, mutation Y453F reduces neutralization by an antibody with emergency use authorization for coronavirus disease 2019 (COVID-19) therapy and sera/plasma from COVID-19 patients. These results suggest that antibody responses induced upon infection or certain antibodies used for treatment might offer insufficient protection against SARS-CoV-2 variants from mink.
Keywords: SARS-CoV-2; Y453F; antibodies; evasion; mink; mutation; neutralization; spike protein; variant.